Rheumatoid arthritis and the impact of genetic factors on mortality

April 27, 2007

A chronic autoimmune disease, rheumatoid arthritis (RA) is marked by inflammation that takes a progressive toll on not only the joints, but also various organs and the whole body. RA sufferers, as many studies have shown, tend to face a high risk for early death, increasing with the severity of their symptoms. The most prevalent cause of death among RA patients is cardiovascular disease. As in the general population, classic factors such as age, hypertension, diabetes, and smoking have been implicated in the RA death rate. Little is known, however, about the specific influence of genetic factors on mortality.

To investigate the genetic risk for early death in RA, researchers in the United Kingdom targeted a likely suspect, already associated with disease susceptibility and severity: the HLA-DRB1 alleles encoding the shared epitope (SE), a region involved in antigen recognition. Their findings, featured in the May issue of 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), suggest an increased risk of death for RA patients with HLA-DRB1 SE genotypes. In particular, the presence of 2 SE alleles was strongly linked to a high risk of early death from heart disease or cancer.

The study focused on a subgroup of patients recruited between 1986 and 1997 for the Early RA study (ERAS), a UK-based long-term, multicenter study of disease outcomes and predictive features. HLA-DRB1 genotyping was carried out on blood samples from 767 patients with follow-up over 18 years. Of the total subjects, 186 (24 percent) had died, of whom 80 were men and 106 were women. Dates and causes of death were obtained for all. The 2 major causes of death were cardiovascular disease (28.2 percent) and malignancy (24.7 percent). The most common primary cause of death was ischemic heart disease (23 percent). The most common malignancy-related cause of death was lung cancer, which accounted for 14 of the 46 cancer deaths (30.4 percent).

Using Cox proportional hazards regression analyses, researchers gauged the association of HLA-DRB1 alleles with risk of mortality. They also used multivariate stepwise models to assess the predictive value of HLA-DRB1 genotypes compared with other potential risk factors.

Of the patients who died from heart disease or cancer, 29 (32.6 percent) carried 2 HLA-DRB1 SE alleles. What's more, patients who had 2 SE alleles generally died younger than all other patients. This was especially striking in patients who died of ischemic heart disease; those carrying 2 SE alleles died at a mean age of 67.8 years. Another surprising discovery was that patients with the 2 alleles had no clinical evidence of heart disease up to 1 year before dying of a heart attack.

"Our data raise the possibility that a higher risk of sudden cardiac death is associated with particular HLA-DRB1 genotypes that are more frequent in patients with RA," note the study's lead authors, Dr. D Mattey and Dr. A. Young, affiliates of the National Health Service Trust. "Further studies are needed to determine whether clinically silent ischemic heart disease in RA is associated with certain HLA-DRB1 genotypes, and whether this can explain in part the higher risk of sudden death in these patients."

As Dr. Mattey and Dr. Young admit, their team cannot offer an explanation for the association of these 2 SE alleles with increased risk of death from heart disease or cancer in RA patients. They also acknowledge the study's limitations, including the relatively small and racially homogenous sample (all subjects were Caucasian), the incomplete information on patients' smoking status, and the inability to assess the effects of different therapies on mortality. "Treatment recommendations have changed substantially since the ERAS was first initiated," they observe. "Thus, further studies are necessary to determine the impact of DRB1 genotypes on mortality under current treatment regimens. It has been suggested that methotrexate and TNF inhibitors reduce the risk of cardiovascular death in RA, so the association between specific DRB1 genotypes and mortality may be modified by more aggressive treatment in those patients with genotypes that predispose to more severe disease."
-end-
Article: "Association of DRB1 Shared Epitope Genotypes With Early Mortality in Rheumatoid Arthritis: Results of Eighteen Years of Follow Up From the Early Rheumatoid Arthritis Study," D.L. Mattey, W. Thomson, W.E.R. Ollier, M. Batley, P.G. Davies, A.K. Gough, J. Devlin, P. Prouse, D.W. James, P.L. Williams, J. Dixey, J. Winfield, N.L. Cox, G. Koduri, and A. Young, Arthritis & Rheumatism, May 2007; (DOI: 10.1002/art.22527).

Wiley

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.